IFPMA was instrumental in establishing the AMR Industry Alliance, as the life sciences industry’s collective response to tackle AMR.

In 2016, the United Nations called for action from governments and various sectors to comprehensively address the implications of AMR and implement strategies at national level. The AMR Industry Alliance is the life sciences industry’s response.Today, the Alliance brings together over 100 biotech, diagnostics, generics, and research-based pharmaceutical companies and associations to collaborate, provide solutions, and report on progress.

The  Alliance is guided by two founding documents – the Davos Declaration and the Industry Roadmap. These commitments have evolved over time to reflect industry progress and global priorities.

Looking ahead, continued cross-sector collaboration, supported by policy and regulatory changes that enable a sustainable marketplace, will be critical to ensuring innovation and access to effective antibiotics for future generations.

The AMR Industry Alliance is leading global efforts to ensure responsible antibiotic manufacturing, providing science-driven standards and guidance to manufacturers in the global antibiotic supply chain to make sure their antibiotics are made responsibly.

This work has has included:

• Science-based targets: Developed antibiotic discharge targets and published research establishing default predicted no-effect concentrations (PNECs) for antibiotics, guiding manufacturers to minimize environmental impact. The PNEC tables are continuously updated.
• Framework to promote responsible antibiotic manufacturing: This included describing a risk-based approach to assessing and controlling antibiotic manufacturing waste streams.
• Antibiotic Manufacturing Standard, facilitated by BSI Standards Limited (BSI): Launched in 2022 and updated in 2025 to align with WHO guidance, this is the only independently certifiable standard for responsible antibiotic production. Since 2023, BSI has certified over 60 antibiotic products across 15 countries, with the revised standard rolling out in 2026.

The Alliance continues to collaborate with stakeholders, share best practices, and engage in scientific discussion to expanding the knowledge-base, developing and improving ways to assess risks, and optimizing strategies to deal with AMR, without compromising patient access to necessary medicines.